A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Ravulizumab (Primary)
- Indications Haemolytic uraemic syndrome
- Focus Therapeutic Use
- Sponsors Alexion Pharmaceuticals
- 27 Jul 2017 According to an Alexion media release, the company expects to initiate this study in third quarter of 2017.
- 24 Apr 2017 Status changed from planning to not yet recruiting.
- 16 Feb 2017 According to an Alexion media release, the company expects to initiate this study in the second quarter of 2017.